Abstract 5003
Background
The European Commission has a long-term commitment to reducing cancer burden in the EU. Evaluation of the effectiveness of measures implemented is dependent on accurate and comparable data allowing derivation of cancer indicators (incidence, mortality, survival). For this purpose, the EC Joint Research Centre (JRC) in close collaboration with DG SANTE is maintaining a comprehensive cancer information system for Europe.
Methods
Population-based cancer registries (CRs) are the information source for the computation of cancer burden indicators. In response to the call from the Council to the Commission to act further in harmonising EU cancer registration, the JRC since 2012 has taken an active role in supporting the activities and exploiting the data of the CRs affiliated to the European Network of Cancer Registries (ENCR).
Results
The JRC has developed and launched in February 2018 the European Cancer Information System (ECIS) as a web-based tool to report and disseminate cancer burden indicators. The ECIS displays historical time series and projections of cancer incidence and mortality, as well as cancer survival indicators. Statistics in the ECIS are derived from the data of about 150 CRs in 34 European countries, detailing up to 58 cancers sites. The database feeding the ECIS is dynamic and is updated as new data become available.
Conclusions
ECIS permits the exploration of geographical patterns and temporal trends of cancer burden indicators at national and/or regional level. It constitutes an essential tool to promote awareness on cancer burden, to assess and monitor its magnitude and follow trends and changes over time. ECIS is an important step forward in informing the citizens, assisting political decision making and supporting epidemiological research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
European Commission.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2162 - Clinical Benefit and Prices of Cancer Drugs in the US and Europe
Presenter: Kerstin Vokinger
Session: Poster Discussion - Public policy
Resources:
Abstract
4743 - Determinants of the Cancer Drug Funding Process in Canada
Presenter: Joanna Gotfrit
Session: Poster Discussion - Public policy
Resources:
Abstract
6081 - Biosimilar Substitution: European Prescriber Perspectives
Presenter: Michael Reilly
Session: Poster Discussion - Public policy
Resources:
Abstract
1218 - Cost avoided in drugs derived from participation in clinical trials in colorectal cancer
Presenter: Luis Sánchez- Rubio Ferrández
Session: Poster Discussion - Public policy
Resources:
Abstract
3453 - Accessibility and Affordability to Trastuzumab for Breast cancer patients: voices of the Global Oncology community from ONCOLLEGE 001 survey – part 2
Presenter: Sara Altuna
Session: Poster Discussion - Public policy
Resources:
Abstract
3302 - Poster Discussion - Public policy - Analysis of 105.000 cancer patients; have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands
Presenter: Janneke Walraven
Session: Poster Discussion - Public policy
Resources:
Abstract
5246 - Reaching sustainable oncology care via the National Cancer Control Program (NCCP)
Presenter: Branko Zakotnik
Session: Poster Discussion - Public policy
Resources:
Abstract
5586 - Changing landscape of clinical cancer trials in Germany
Presenter: Susen Burock
Session: Poster Discussion - Public policy
Resources:
Abstract
5192 - Comparison between phase III randomized clinical trials and their preceeding phase II studies.
Presenter: Ivan Lyra-Gonzalez
Session: Poster Discussion - Public policy
Resources:
Abstract
5811 - Projecting overall survival data for health-economic models in oncology: do maturity levels impact uncertainty?
Presenter: Isabelle Borget
Session: Poster Discussion - Public policy
Resources:
Abstract